176-64-7

Usage

Uses

Used in Chemical Industry:
8-Azaspiro[4.5]decane is used as an intermediate compound for the synthesis of various organic compounds. Its unique spiro structure allows for the creation of complex molecules that can be used in a wide range of applications.
Used in Pharmaceutical Industry:
8-Azaspiro[4.5]decane is used as a building block in the development of new pharmaceuticals. Its spiro structure can be incorporated into drug molecules to improve their stability, solubility, or biological activity, potentially leading to more effective treatments for various diseases.
Used in Organic Synthesis:
8-Azaspiro[4.5]decane is used as a key component in the synthesis of complex organic molecules. Its spiro structure can be utilized to create novel compounds with unique properties, which can be further explored for potential applications in various fields.
Used in Research and Development:
8-Azaspiro[4.5]decane is used as a research compound for studying the properties and potential applications of spiro structures in chemistry and medicine. This can lead to a better understanding of the underlying mechanisms and the development of new strategies for the synthesis and application of these compounds.

InChI:InChI=1/C9H17N/c1-2-4-9(3-1)5-7-10-8-6-9/h10H,1-8H2

Upstream product

• 501-53-1 benzyl chloroformate 
• 1075-89-4 tetramethylene glutarimide 

Downstream Products

• 262861-05-2 [2-(8-Azaspiro[4.5]dec-8-yl)phenyl]ethanon 
• 263408-19-1 2-(8-Azaspiro[4.5]dec-8-yl)benzonitril 
• 263408-21-5 2-(8-Azaspiro[4.5]dec-8-yl)benzaldehyd 
• 291544-98-4 2-(8-Azaspiro[4.5]dec-8-yl)benzophenon 
• 137795-38-1 (R)-5-(8-Aza-spiro[4.5]dec-8-yl)-4-(3-methyl-benzoylamino)-5-oxo-pentanoic acid 
• 137795-40-5 (R)-5-(8-Aza-spiro[4.5]dec-8-yl)-4-(3,5-dimethyl-benzoylamino)-5-oxo-pentanoic acid 
• 137795-39-2 (R)-5-(8-Aza-spiro[4.5]dec-8-yl)-4-(3-ethyl-benzoylamino)-5-oxo-pentanoic acid 
• 137795-45-0 (R)-5-(8-Aza-spiro[4.5]dec-8-yl)-4-(3-bromo-benzoylamino)-5-oxo-pentanoic acid 
• 137795-41-6 (R)-5-(8-Aza-spiro[4.5]dec-8-yl)-4-(4-isopropyl-benzoylamino)-5-oxo-pentanoic acid 
• 137795-42-7 (R)-5-(8-Aza-spiro[4.5]dec-8-yl)-4-(3-methoxy-benzoylamino)-5-oxo-pentanoic acid 
• 137795-44-9 (R)-5-(8-Aza-spiro[4.5]dec-8-yl)-4-(3-cyano-benzoylamino)-5-oxo-pentanoic acid 
• 137795-37-0 (R)-5-(8-Aza-spiro[4.5]dec-8-yl)-4-(2,3-dichloro-benzoylamino)-5-oxo-pentanoic acid 
• 137795-43-8 (R)-5-(8-Aza-spiro[4.5]dec-8-yl)-4-(3-nitro-benzoylamino)-5-oxo-pentanoic acid 
• 137795-46-1 (R)-5-(8-Aza-spiro[4.5]dec-8-yl)-5-oxo-4-(3-trifluoromethyl-benzoylamino)-pentanoic acid 

Relevant academic research and scientific papers

Compound as potassium channel modulator

The invention relates to a compound as a potassium channel modulator, which is a compound of a formula (I) or a pharmaceutically acceptable salt thereof. The compound or the pharmaceutically acceptable salt thereof is effective for curing and preventing diseases and symptoms influenced by the activity of potassium ion channels.

Benzoxazinone derivatives and their use as antibacterial agents

The invention discloses benzoxazinone derivatives, a synthesis method and applications thereof. The derivatives can be used as an antibacterial agent for treating infectious diseases caused by bacteria, especially tuberculosis (TB) caused by mycobacterium. Specifically, the invention relates to compounds represented by the formula (I), pharmaceutically acceptable salts thereof, and a pharmaceutical composition comprising the provided compounds; wherein the R1 to R4 are defined in the description. The invention aim to prepare novel compounds capable of inhibiting the mycobacterium activity, the compounds can be used as a potential novel drug for treating infectious diseases caused by bacteria, moreover, the compounds can be used to treat or prevent tuberculosis (TB) caused by mycobacterium, at the same time the problems related with drug resistance can be solved, and the drug metabolism property can be improved on the basis that the mycobacterium tuberculosis resistant activity is not influenced.

SPIRO AMINO COMPOUNDS SUITABLE FOR THE TREATMENT OF INTER ALIA SLEEP DISORDERS AND DRUG ADDICTION

The invention concerns a spiro-amino compound of Formula (Vl) wherein m is 1 or 2 or 3, n is 1 or 2, R is selected from a 5- or 6-membered aromatic ring and a 5- or 6-membered heteroaromatic ring comprising 1 to 3 heteroatoms selected from S, O e N, such ring being substituted with one or two substituents selected from the group consisting of (C1-C3)alkyl, halogen, (C3-C5)cycloalkyloxy, (C1-C3)alkylcarbonyl, phenyl optionally substituted with one or more halogen atoms, a 5- or 6-membered heterocycle comprising at least one nitrogen atom; P is a substituent Q or COQ, wherein Q is selected from the group consisting of phenyl, pyridil, pyrimidil, quinolyl, isoquinolyl, quinoxalyl, benzofuranyl, imidazotriazolyl, being such Q optionally substituted with one or more substituents selected from the group consisting of (C1-C3)alkyl, halogen, trifluoromethyl, carbammido, methylcarbammido, carboxy, methylcarboxy or a pharmaceutically acceptable salt thereof.

Discovery of spiro-piperidine inhibitors and their modulation of the dynamics of the M2 proton channel from influenza A virus

Amantadine has been used for decades as an inhibitor of the influenza A virus M2 protein (AM2) in the prophylaxis and treatment of influenza A infections, but its clinical use has been limited by its central nervous system (CNS) side effects as well as emerging drug-resistant strains of the virus. With the goal of searching for new classes of M2 inhibitors, a structure-activity relation study based on 2-[3-azaspiro(5,5)undecanol]-2-midazoline (BL-1743) was initiated. The first generation BL-1743 series of compounds has been synthesized and tested by two-electrode voltage-clamp (TEV) assays. The most active compound from this library, 3-azaspiro[5,5]undecane hydrochloride (9), showed an IC50 as low as0.92 ± 0.11 μM against AM2, more than an order of magnitude m ore potent than amantadine (IC50 = 16 μM). 15N and 13C solid-state NMR was employed to determine the effect of compound 9 on the structure and dynamics of the transmembrane domain of AM2 (AM2-TM) in phospholipid bilayers. Compared to amantadine, spiro-piperidine 9 (1) induces a more homogeneous conformation of the peptide,(2) reduces the dynamic disorder of the G34-I35 backbone near the water -filled central cavity of the helical bundle, and (3) influences the dynamics and magnetic environment of more residues within the transmembranehelices. These data suggest that spiro-piperidine 9 binds more extensiv ely with the AM2 channel, thus leading to stronger inhibitory potency.

Cyclic hexapeptides having antibiotic activity

This invention relates to new polypeptide compound represented by general formula (I), wherein R1, R2, R3, R4, R5 and R6 are as defined in the description or a salt thereof which has antimicrobial activities (especially, antifungal activities), inhibitory activity on β-1,3-glucan synthase, to process for preparation thereof, to a pharmaceutical composition comprising the same, and to a method for prophylactic and/or therapeutic treatment of infectious diseases including Pneumocystis carinii infection (e.g. Pneumocystis carinii pneumonia) in a human being or an animal.

Substituted benzothiazole amide derivatives

A compound of formula I and a method of treatment of diseases, related to modulation of the adenosine A2 receptor system comprising administering a compound of formula 1to a person in need of such treatment.